L'incidenza è di 3 casi/100.000 abitanti all'anno con probabilità di rottura del 2/ 100.000. Il che signiﬁca che in Italia ci sono circa 1800 nuovi casi ogni anno.

Background St. Thomas (ST) and Del Nido (DN) cardioplegic solutions are widely used for myocardial protection during cardiac surgery. In 2016, our university hospital shifted from modified St. Thomas to Del Nido solution for both adult and pediatric cardiac surgery.

Del Nido cardioplegia was initially used in pediatric patients and has been expanding into adult cardiac centers over the last decade. Del Nido cardioplegia is routinely used in clinical practice both in paediatric and adult population in high volume centres. It could be a safe, effective and cheap myocardial protection strategy of universal implementation in cardiac surgery. Additional prospective studies are needed to confirm these data.

It has been used for pediatric cardiac surgery in Boston’s Children Hospital since 1994 and, since 2003, it has been success-fully used for adult cardiac surgery as well [8]. Download Citation | Use of del Nido Cardioplegia in Adult Cardiac Surgery | Background del Nido cardioplegia was developed to protect pediatric hearts, and similar to pediatric hearts, older adult 1.0-liter of del Nido Cardioplegia after the aortic cross-clamp is applied to the ascending aorta. Delivery of del Nido solution will be administered in a 1:4 ratio of blood:crystalloid at a temperature of 6-10 degrees centigrade. Conclusion: Del Nido cardioplegia is safe and can be used efficiently as an alternative to blood cardioplegia in isolated aortic valve replacement surgery.

The del Nido solution was formulated by researchers from the University of Pittsburgh (Pittsburgh, PA, USA) in the early 1990s [ 5]. The evolution of myocardial protection techniques has been both the source of milestone advancements and controversial debate in cardiac surgery.

del Nido cardioplegia is a newer solution getting popular worldwide, whereas in Nepal, St. Thomas cardioplegia solution is conventionally used. There is no national recommendation on cardioplegia solutions supported by evidences from Nepalese studies.

There is no national recommendation on cardioplegia solutions supported by evidences from Nepalese studies. Del Nido cardioplegia Del Nido cardioplegia was developed by Pedro Del Nido and his team at the University of Pittsburgh in 1990s. It has been used for pediatric cardiac surgery in Boston’s Children Hospital since 1994 and, since 2003, it has been successfully used for adult cardiac surgery as well [8]. 2016-12-30 Del Nido vs.

Se hela listan på academic.oup.com

OBJECTIVES: Del Nido cardioplegia is a non-glucose-based solution given as a single dose that provides up to 180 minutes of cardiac quiescence. The del Nido solution (DNS) has been used safely for nearly two decades at a single center in both pediatric and adult patients.

Cardioplegia is an integral and essential method of myocardial protection for patients of all ages requiring cardiac surgery in which the heart must be stopped. Modifications have been made to the original solution and it is now referred to as del Nido cardioplegia in the literature and in clinical practice. Composition of del Nido and Blood Cardioplegia Solutions Del Nido solution is composed of mixed blood and Plasma-Lyte A (1:4) (total volume: 1060 mL). Mannitol (3.26 g), potassium chloride (K, 26 mEq), magnesium sulphate (Mg, 2 g), lidocaine (130 mg), and sodium bicarbonate (13 mEq) were added to the del Nido solution. As a leader in the industry, CAPS offers Cardioplegia with the highest quality standards, including batch level release testing and extended beyond use dating. Test, Hold and Release® (THR®) is CAPS' quality assurance program in response to the cGMP level standards created by the Drug Quality and Security Act (DQSA) for 503B facilities engaged in batched compounding without a prescription. Del Nido (DN) cardioplegia was formulated to act as single-dose administration in pediatric patients.
Flygplanskrascher

Aortic Valve. Cardiopulmonary Bypass. Heart Arrest, Induced. Cardiovascular Agents. Heart Valve Prosthesis.

Cardiopulmonary Bypass. Heart Arrest, Induced. Cardiovascular Agents. Heart Valve Prosthesis.
Nikkei stock

Conclusions: It is safe to use del Nido cardioplegia in coronary artery bypass grafting combined with heart valve replacement in adults, which can reduce the frequency of cardioplegia infusion and simplify the surgical procedure. The trend of troponin concentration suggests that del Nido cardioplegia has a better myocardial protective effect.

Additional prospective studies are needed to confirm these data.